Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested ...

Melanoma is amongst the most lethal types of skin cancer. Although advances like checkpoint immunotherapy have improved outcomes in recent years, only 40% of patients respond and it remains difficult ...

Data on each of Castle’s skin cancer tests, as outlined below ... The results of the analysis was shared in a poster titled, “The 31-gene expression profile test stratifies the risk of ...

and a poster presentation on the tumor-targeting bispecific REGN5093 (designed to target two different parts of the MET receptor on cancer cells to degrade the receptor and block its ability to ...

today announced that new data supporting the clinical value of the Company’s skin cancer test portfolio is being shared in poster presentations at the 2023 Winter Clinical Dermatology Conference ...

People who use skin lightening products that contain hydroquinone may be at an increased risk for skin cancers ... of the study were presented in a poster at the Society for Investigative ...

Skin cancer can involve melanocytes ... with epigenetic changes and altered antigen presentation potentially contributing to this effect.

Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE ...